Seven COVID+Influenza combination vaccine candidates in active clinical development:
- Novavax CIC nanoparticle (NCT04961541, NCT05519839)
- Moderna mRNA-1083 (NCT06097273; NCT05375838, NCT05827926)
- Moderna mRNA-1230, including RSV (NCT05585632)
- Pfizer/BioNTech modRNA (NCT05596734)
- GSK/CureVac mRNA (NCT06680375)
- Sanofi RIV3+NVXC19 (NCT06695130)
- Sanofi TIV-HD + NVXC19 (NCT06695117)